Evidence map›Paper›PMID 39531610›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL.

Motohiro Kato, Yasuhiro Okamoto, Toshihiko Imamura, Akiko Kada, Akiko M Saito, Yuka Iijima-Yamashita, Takao Deguchi, Kentaro Ohki, Takashi Fukushima, Kenichi Anami and 17 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. CAR-T cells with the CD38Cell reports. Medicine · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Motohiro KatoDepartment of Pediatrics, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-5145-1774
Yasuhiro OkamotoDepartment of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0003-4412-6441
Toshihiko ImamuraDepartment of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Akiko KadaClinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.ORCID 0000-0001-6350-5389
Akiko M SaitoClinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.ORCID 0000-0003-3723-8445
Yuka Iijima-YamashitaClinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.ORCID 0000-0003-3954-258X
Takao DeguchiChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.ORCID 0000-0001-9932-4299
Kentaro OhkiDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.ORCID 0000-0003-2838-4555
Takashi FukushimaDepartment of Child Health, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Kenichi AnamiDepartment of Medical Oncology, Hematology, and Infectious Diseases, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Masashi SanadaClinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.ORCID 0000-0003-0666-1996
Tomohiko TakiDepartment of Medical Technology, Kyorin University Faculty of Health Sciences, Mitaka, Japan.
Yoshiko HashiiDepartment of Pediatrics, Osaka University, Suita, Japan.
Takeshi InukaiDepartment of Pediatrics, University of Yamanashi, Chuo, Japan.
Nobutaka KiyokawaDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.ORCID 0000-0001-9310-2126
Yoshiyuki KosakaDepartment of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Nao YoshidaDepartment of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital, Nagoya, Japan.
Yuki YuzaDepartment of Hematology-Oncology, Tokyo Metropolitan Children's Medical Center, Fuchu, Japan.ORCID 0009-0003-6475-3394
Masakatsu YanagimachiDivision of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Kenichiro WatanabeDepartment of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan.ORCID 0000-0002-8892-3082
Atsushi SatoDepartment of Hematology and Oncology, Miyagi Children's Hospital, Sendai, Japan.
Chihaya ImaiDepartment of Pediatrics, University of Toyama, Toyama, Japan.ORCID 0000-0001-7435-3464
Takashi TagaDepartment of Pediatrics, Shiga University of Medical Science, Otsu, Japan.
Souichi AdachiDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Keizo HoribeClinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.ORCID 0000-0002-6251-6059
Atsushi ManabeDepartment of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan.ORCID 0000-0002-6698-2348
Katsuyoshi KohDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.ORCID 0000-0002-0476-4978

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe JCCG ALL-B12 clinical trial aimed to evaluate the effectiveness of unvalidated treatment phases for pediatric ALL and develop a safety-focused treatment framework. PATIENTS AND

methodsPatients age 1-19 years with newly diagnosed B-ALL were enrolled in this study. These patients were stratified into standard-risk (SR), intermediate-risk (IR), and high-risk (HR) groups. Randomized comparisons assessed the effectiveness of vincristine (VCR)/dexamethasone pulses in the SR group, evaluated the effects of L-asparaginase (ASP) intensification in the IR group, and compared standard consolidation including block-type treatment with experimental consolidation with high-dose methotrexate (HD-MTX) intensified with VCR and ASP in the HR group.

resultsOf 1,936 patients enrolled, 1,804 were eligible for the experimental treatment. The overall 5-year event-free survival and overall survival rates were 85.2% (95% CI, 83.5 to 86.8) and 94.3% (95% CI, 93.1 to 95.3), respectively. The cumulative incidence of relapse and postremission nonrelapse mortality was 13.2% (95% CI, 11.6 to 14.8) and 0.6% (95% CI, 0.3 to 1.0), respectively. Random assignment in the SR group showed no significant benefit from pulse therapy. In the IR group, ASP intensification had limited effects. In the HR group, standard block therapy and HD-MTX yielded equivalent outcomes.

conclusionThe ALL-B12 trial achieved favorable outcomes in a nationwide cohort by stratifying treatment on the basis of risk and balancing treatment intensity. This study not only demonstrated that existing standard of care can be further refined but also indicated that improvement in outcomes with intensified chemotherapy has reached a plateau.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdolescentAsparaginaseChildChild, PreschoolDexamethasoneFemaleHumansInfantMaleMethotrexateVincristineYoung AdultAsparaginaseDexamethasoneMethotrexateVincristine

Identifiers

PMID39531610
PMCPMC11809717

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.